Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/chf.12022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hypertension remains a significant global health issue, increasingly affecting younger populations due to lifestyle and dietary changes. This case report presents a 28-year-old male diagnosed with primary hyperaldosteronism, a rare but treatable cause of secondary hypertension, presenting as hypertensive urgency. The patient reported persistent headaches and weakness, with an initial blood pressure of 190/120 mmHg and severe hypokalemia.
View Article and Find Full Text PDFApplying the 'touch-and-go' concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management.
Eur J Heart Fail
December 2024
Université de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France.
Comparative Efficacy and Long-Term Outcomes of Beta-Blockers Alone or in Combination With Angiotensin-Converting Enzyme (ACE) Inhibitors in Chronic Heart Failure: A Systematic Review.
Cureus
November 2024
Internal Medicine, Nishtar Medical University, Multan, PAK.
This systematic review provides a comprehensive comparison of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors in the management of chronic heart failure (CHF), with a focus on their long-term efficacy and safety profiles. By synthesizing evidence from randomized controlled trials (RCTs) and clinical studies, the review highlights the significant benefits of both drug classes in reducing mortality and hospital readmissions, and improving patient outcomes. Beta-blockers, such as bisoprolol and carvedilol, demonstrated superior efficacy in reducing sudden cardiac death, particularly in patients with heart failure with reduced ejection fraction (HFrEF).
View Article and Find Full Text PDFPossible antihypertensive effects of mineralocorticoid receptor antagonists other than reducing extracellular water.
Hypertens Res
December 2024
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Prospective registry of heart failure with preserved ejection fraction in México: EDIFICE-Mx.
Am Heart J Plus
December 2024
National Institute of Cardiology Ignacio Chavez, Coronary Care Unit, Mexico City, Mexico.
Background And Aims: Heart failure with preserved ejection fraction (HFpEF) is an increasingly common clinical syndrome, estimated to constitute approximately 50 % of all heart failure (HF) cases. Nonetheless, registries from specific geographic areas, as Latin America, are lacking. The present study aims to report the underlying causes, comorbidities, treatment patterns and outcomes of patients with HFpEF in a large cardiovascular center in Mexico City.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!